US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström

Company release Nanoform Finland Plc November 19, 2024 20.45 Finnish time / 19.45 Swedish time Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s Member of the Board and CFO Albert Hæggström’s purchase of Nanoform Finland Plc shares: Nanoform Finland Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Albert Haeggström Position: Member of the Board/Deputy member  Issuer: Nanoform Finland Oyj

Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen

Company release Nanoform Finland Plc November 19, 2024 20.45 Finnish time / 19.45 Swedish time Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s General Counsel and Chief Development Officer Peter Hänninen’s purchase of Nanoform Finland Plc shares: Nanoform Finland Oyj - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Peter Hänninen Position: Other senior manager  Issuer: Nanoform FInland Oyj LEI:

Nanoform Q3 2024 report: Record number of new projects signed

Company Announcement Nanoform Finland Plc November 18, 2024 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Q3 2024 report: Record number of new projects signed A record number of new non-GMP projects signed in the quarter, helped by a significantly increased interest in our Biologics offering. Revenue growth is back and is expected to accelerate in coming quarters and years. Most GMP Quality Control analytical activities insourced after receiving Fimea license in August. Manufacturing of GMP material for pivotal studies and registration batches in Project

Invitation to Nanoform’s Q3 2024 Report Presentation

Press release Nanoform Finland Plc November 4, 2024 11:00 a.m. Finnish time / 10:00 a.m. Swedish time Invitation to Nanoform’s Q3 2024 Report Presentation Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, will publish its Q3 2024 report November 18th, 2024, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time. The company will hold an online presentation and conference call the same day at 3.00 p.m. Finnish time / 2.00 p.m. Swedish time. Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström and CCO

Disclosure as attachment of the Nanoform 2022 Report of the Board of Directors and Financial Statements which were previously linked to a Company Release

Company release Nanoform Finland Plc October 25, 2024 16.15 Finnish time / 15.15 Swedish time Disclosure as attachment of the Nanoform 2022 Report of the Board of Directors and Financial Statements which were previously linked to a Company Release Nanoform Finland Plc reported February 28, 2023, FY2022 results with a Company Release including Financial Statements Review for January-December 2022. In the Company Release the link to all additional documents were provided, including ‘Report of the Board of Directors and Financial Statements’, in English and Finnish. The ‘

Share subscriptions based on Nanoform Finland Plc’s stock options 2/2019

Company release Nanoform Finland Plc October 22, 2024 19.20 Finnish time / 18.20 Swedish time Share subscriptions based on Nanoform Finland Plc’s stock options 2/2019 A total of 1,000 Nanoform Finland Plc’s new shares has been subscribed for with the company's stock options 2/2019 on 14 October 2024. For subscriptions made with the stock options 2/2019 the entire subscription price of EUR 1,100.00 will be entered in the reserve for invested unrestricted equity. After the trade registration, the total number of shares is 85,531,236. The shares subscribed for under the stock

Nanoform and Celanese Expand Collaboration into Long-Acting Biologics Delivery Through Small Implants

Press release Nanoform Finland Plc September 5, 2024 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform and Celanese Expand Collaboration INTO Long-Acting BIOLOGICS DELIVERY THROUGH SMALL IMPLANTS Helsinki, Finland & Dallas, US – September 5, 2024 - Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, and Celanese Corporation (“Celanese”), a global specialty materials and chemical company, today announced an expansion of their collaboration to cover biologic drug delivery. The companies will combine Nanoform’s Biologics platform

Nanoform Q2 report: All business targets for 2024 on track

Company Announcement Nanoform Finland Plc August 29, 2024 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Q2 report: All business targets for 2024 on track Manufacturing of GMP material in project nanoenzalutamide continues. One or several license/commercial supply agreements are expected to be signed during 2024. Our product kernel build-out progresses well. Fimea approved our new GMP QC laboratory. A preclinical development agreement was announced with Takeda. After a burst of signings in early 3Q, including multi-API non-GMP deals with both a new and an existing

Invitation to Nanoform’s Q2 2024 Report Presentation

Press release Nanoform Finland Plc August 16, 2024 11:00 a.m. Finnish time / 10:00 a.m. Swedish time Invitation to Nanoform’s Q2 2024 Report Presentation Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, will publish its Q2 2024 report August 29[th], 2024, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time. The company will hold an online presentation and conference call the same day at 3.00 p.m. Finnish time / 2.00 p.m. Swedish time. Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström and CCO

NANOFORM COLLABORATES WITH TAKEDA ON THEIR PLASMA-DERIVED THERAPY DEVELOPMENT

Press release Nanoform Finland Plc August 15, 2024 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform COLLABORATES WITH TAKEDA on THEIR PLASMA-DERIVED Therapy Development Helsinki, Finland – August 15, 2024 - Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, today announced that it is to enter into a pre-clinical development agreement with the Plasma-derived Therapies Business Unit of Takeda Pharmaceuticals, Inc., the R&D-driven biopharmaceutical company headquartered in Japan, to develop innovative plasma-derived therapy formulations for

Nanoform Finland Plc – Manager’s Transactions – Miguel Calado

Company release Nanoform Finland Plc June 14, 2024 17.01 Finnish time / 16.01 Swedish time Nanoform Finland Plc – Manager’s Transactions – Miguel Calado Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s Chairman of the Board Miguel Calado’s purchase of Nanoform Finland Plc shares: Nanoform Finland Oyj - Managers' Transactions Person subject to the notification requirement Name: Miguel Calado Position: Member of the Board/Deputy member Issuer: Nanoform Finland Oyj LEI: 743700JJO2NU8LBS1592 Notification type: INITIAL NOTIFICATION

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström

Company release Nanoform Finland Plc June 14, 2024 17.01 Finnish time / 16.01 Swedish time Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s Member of the Board Albert Hæggström’s purchase of Nanoform Finland Plc shares: Nanoform Finland Oyj - Managers' Transactions Person subject to the notification requirement Name: Albert Hæggström Position: Member of the Board/Deputy member  Issuer: Nanoform Finland Oyj LEI: 743700JJO2NU8LBS1592 Notification type: INITIAL

Nanoform Finland Plc – Manager’s Transactions – Mads Laustsen

Company release Nanoform Finland Plc June 14, 2024 17.01 Finnish time / 16.01 Swedish time Nanoform Finland Plc – Manager’s Transactions – Mads Laustsen Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s Member of the Board Mads Laustsen’s purchase of Nanoform Finland Plc shares: Nanoform Finland Oyj - Managers' Transactions Person subject to the notification requirement Name: Mads Laustsen Position: Member of the Board/Deputy member  Issuer: Nanoform Finland Oyj LEI: 743700JJO2NU8LBS1592 Notification type: INITIAL NOTIFICATION

Nanoform Finland Plc – Manager’s Transactions – Jeanne Thoma

Company release Nanoform Finland Plc June 14, 2024 17.01 Finnish time / 16.01 Swedish time Nanoform Finland Plc – Manager’s Transactions – Jeanne Thoma Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s Member of the Board Jeanne Thoma’s purchase of Nanoform Finland Plc shares: Nanoform Finland Oyj - Managers' Transactions Person subject to the notification requirement Name: Jeanne Thoma Position: Member of the Board/Deputy member  Issuer: Nanoform Finland Oyj LEI: 743700JJO2NU8LBS1592 Notification type: INITIAL NOTIFICATION

Share subscriptions based on the resolution by Nanoform Finland Plc’s Annual General Meeting 2024 on remuneration of the Board of Directors

Company release Nanoform Finland Plc June 14, 2024 17:00 Finnish time / 16.00 Swedish time Share subscriptions based on the resolution by Nanoform Finland Plc’s Annual General Meeting 2024 on remuneration of the Board of Directors Helsinki, Finland – A total of 85,072 Nanoform Finland Plc’s (the “Company” or “Nanoform“) new shares has been subscribed for by the members of the Board of Directors of the Company.  The shares are issued as part of remuneration of the members of the Board of Directors in accordance with the resolution by the Company’s Annual General Meeting April

Nanoform's biologics technology showcased by large pharma at drug delivery conference; Nanoenzalutamide and nanoapalutamide partnering discussions progress as planned

Company Announcement Nanoform Finland Plc May 30, 2024 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform's biologics technology showcased by large pharma at drug delivery conference; Nanoenzalutamide and nanoapalutamide partnering discussions progress as planned Manufacturing of GMP material in Project Nanoenzalutamide commenced. EU/US pivotal studies are planned to start in 4Q24, with the read-out in 1Q25. One or several license/commercial supply agreements are expected to be signed during 2H24. Fimea’s two-day inspection of our new GMP QC laboratory and new GMP

Disclosure of Major Holdings under Law 163/2024

Company Release Nanoform Finland Plc May 29, 2024 12.30 Finnish time / 11.30 Swedish time Disclosure of Major Holdings under Law 163/2024 Nanoform Finland Plc ("Nanoform" or the "Company") has on May 28, 2024, received a notification from Edward Hæggström (CEO of Nanoform Finland Plc). The notification was made pursuant to law 163/2024 amending the Finnish Securities Market Act (the “Act”). Under the transition rules of the Act, a shareholder in a First North listed company is in required to notify major holdings within two months from the entry into force of the Act. The

Disclosure of Major Holdings under Law 163/2024

Company Release Nanoform Finland Plc May 29, 2024 12.30 Finnish time / 11.30 Swedish time Disclosure of Major Holdings under Law 163/2024 Nanoform Finland Plc ("Nanoform" or the "Company") has on May 28, 2024, received a notification from University of Helsinki Funds. The notification was made pursuant to law 163/2024 amending the Finnish Securities Market Act (the “Act”). Under the transition rules of the Act, a shareholder in a First North listed company is in required to notify major holdings within two months from the entry into force of the Act. The notification has been

Invitation to Nanoform’s Q1 2024 Report Presentation

Press release Nanoform Finland Plc May 16, 2024 11:00 a.m. Finnish time / 10:00 a.m. Swedish time Invitation to Nanoform’s Q1 2024 Report Presentation Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, will publish its Q1 2024 report May 30th, 2024, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time. The company will hold an online presentation and conference call the same day at 3.00 p.m. Finnish time / 2.00 p.m. Swedish time. Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström and CCO Christian Jones.

Nanoformed High-Concentration Biologics Formulation for Subcutaneous Delivery Results to be Presented by Takeda at DDF Summit

Press Release Nanoform Finland Plc May 7, 2024 09.10 EEST / 08.10 CEST Nanoformed High-Concentration Biologics Formulation for Subcutaneous Delivery Results to be Presented by Takeda at DDF Summit Helsinki, Finland – May 7, 2024 – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, today announced that Andreas Liebminger, Ph.D., Global Head of Plasma-derived Therapies Pharmaceutical Sciences, Takeda, is to present data obtained in a proof of concept study, conducted in collaboration with Nanoform, during his presentation titled, “Case Study of a

Disclosure of Major Holdings under Law 163/2024

Company Release Nanoform Finland Plc April 26, 2024 11.00 Finnish time / 10.00 Swedish time Disclosure of Major Holdings under Law 163/2024 Nanoform Finland Plc ("Nanoform" or the "Company") has on April 25, 2024, received a notification from Mandatum Oyj. The notification was made pursuant to law 163/2024 amending the Finnish Securities Market Act (the “Act”). Under the transition rules of the Act, a shareholder in a First North listed company is in required to notify major holdings within two months from the entry into force of the Act. The notification has been made on the

New shares of Nanoform registered with the trade register

Company Release Nanoform Finland Plc April 25, 2024 17.00 Finnish time / 16.00 Swedish time New shares of Nanoform registered with the trade register NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Nanoform Finland Plc ("Nanoform" or the "Company"), an innovative nanoparticle medicine enabling company, announced on April 24, 2024 the result of the offering of new

Nanoform successfully completes new share issue raising EUR 15.4 million to invest in commercialization of nanoparticle enabled formulations for next generation medicines

Inside information Nanoform Finland Plc April 24, 2024 22.50 Finnish time / 21.50 Swedish time Nanoform successfully completes new share issue raising EUR 15.4 million to invest in commercialization of nanoparticle enabled formulations for next generation medicines NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. With reference to the new share issue announced on

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media